Schizophrenia Clinical Trials

81 studies are recruiting for schizophrenia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

   The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

   Stage

   Not phased

   Ages

   18 and older

   Site

   SanRo Clinical Research Group, Bryant, Arkansas

   Locations

   68 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07379827 on ClinicalTrials.gov

2. Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

   The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   TG Therapeutics Investigational Trial Site, Little Rock, Arkansas

   Locations

   2 in total

   Run by

   TG Therapeutics, Inc.

   See if you can join NCT07680946 on ClinicalTrials.gov

3. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Pillar Clinical Research - Bentonville, Bentonville, Arkansas

   Locations

   54 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

4. Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

   This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   Zucker Hillside Hospital, New York, New York

   Run by

   Northwell Health

   See if you can join NCT05389787 on ClinicalTrials.gov

5. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

   The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   CNS Network, Garden Grove, California

   Locations

   8 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07615426 on ClinicalTrials.gov

6. The Effects of Auditory Stimulation During Sleep on Brain Networks in Schizophrenia

   In this research study the investigators will use sleep headbands to measure brain rhythms and to improve their coordination across brain regions. The headbands will be worn at home for multiple nights. On some nights the headbands will play soft sounds at specific times during sleep. The investiga…

   Stage

   Not phased

   Ages

   18 to 45

   Site

   Massachusetts General Hospital, Charlestown, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT06386588 on ClinicalTrials.gov

7. A Study to Evaluate the Effect of KarXT on Urological Safety

   The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Pillar Clinical Research- Little Rock, Little Rock, Arkansas

   Locations

   16 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07221877 on ClinicalTrials.gov

8. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

   The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Advanced Research Center Inc., Anaheim, California

   Locations

   104 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

9. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Little Rock, Arkansas

   Locations

   45 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

10. iTBS to Enhance Social Cognition in People With Psychosis

    The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychotic disorder not otherwise specified. The main objectiv…

    Stage

    Not phased

    Ages

    18 to 39

    Site

    Zucker Hillside Hospital, Glen Oaks, New York

    Run by

    Northwell Health

    See if you can join NCT06118268 on ClinicalTrials.gov

11. A Study of Brenipatide in Adult Participants With Schizophrenia

    The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

    Stage

    Phase 2

    Ages

    18 to 55

    Site

    Pillar Clinical Research- Little Rock, Little Rock, Arkansas

    Locations

    101 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07410507 on ClinicalTrials.gov

12. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

    Stage

    Phase 3

    Ages

    13 to 17

    Site

    Advanced Research Center Inc., Anaheim, California

    Locations

    37 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07288567 on ClinicalTrials.gov

13. Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

    Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the interpersonal aspects of work can lead to isolation, poor productivity, and job loss. The goals of this study are to: 1) …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota

    Run by

    VA Office of Research and Development

    See if you can join NCT05491538 on ClinicalTrials.gov

14. Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

    To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

    Stage

    Phase 4

    Ages

    12 to 17

    Site

    Vanda Investigational Site, Dothan, Alabama

    Locations

    11 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT05648591 on ClinicalTrials.gov

15. Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls

    This study to find out whether a type of non-invasive electrical brain stimulation called transcranial electrical stimulation with temporal interference (TES-TI) can temporarily change brain activity during sleep-especially sleep spindles (brain rhythms in the ~8-16 Hz range). The investigators are…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    University of Wisconsin, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT07680114 on ClinicalTrials.gov

16. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

    The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

    Stage

    Not phased

    Ages

    18 and older

    Site

    ATP Clinical Research - Costa Mesa, Orange, California

    Locations

    20 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07101094 on ClinicalTrials.gov

17. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage

    Phase 3

    Ages

    5 to 17

    Site

    Southwest Autism Research and Resource Center, Phoenix, Arizona

    Locations

    65 in total

    Run by

    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

18. NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Little Rock, Arkansas

    Locations

    20 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07105098 on ClinicalTrials.gov

19. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Bryant, Arkansas

    Locations

    61 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

20. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Garden Grove, California

    Locations

    25 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

21. State Representation in Early Psychosis 2

    This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants. Participants will complete clinical interviews, self-report measures, cognitive assessments, computerized behavi…

    Stage

    Not phased

    Ages

    15 to 45

    Site

    University of Minnesota Ambulatory Research Center, Minneapolis, Minnesota

    Locations

    2 in total

    Run by

    University of Minnesota

    See if you can join NCT07834203 on ClinicalTrials.gov

22. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Neurocrine Clinical Site, Bryant, Arkansas

    Locations

    19 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07105111 on ClinicalTrials.gov

23. A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

    The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amou…

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    Pillar Clinical Research, LLC, Little Rock, Arkansas

    Locations

    10 in total

    Run by

    Leal Therapeutics, Inc

    See if you can join NCT07734493 on ClinicalTrials.gov

24. Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)

    Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS a…

    Stage

    Not phased

    Ages

    22 to 65

    Site

    The University of Texas Health Science Center, Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT05276050 on ClinicalTrials.gov

25. A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

    Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult part…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Woodland International Research Group /ID# 275747, Little Rock, Arkansas

    Locations

    7 in total

    Run by

    AbbVie

    See if you can join NCT07145918 on ClinicalTrials.gov